Zosano Pharma is an emerging CNS company focusing on providing rapid symptom relief to patients, using known therapeutics with well-established safety and efficacy.
Location: United States, California, Fremont
Employees: 11-50
Total raised: $15.4M
Founded date: 2006
Investors 4
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | Hercules C... | htgc.com |
| - | Vivo Capit... | vivocapita... |
| - | Trinity Ca... | trinitycap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 09.02.2022 | - | $15.4M | - |
Mentions in press and media 10
| Date | Title | Description |
| 29.10.2024 | Characterization of Microneedle Products: Useful Methods and Approaches, Upcoming Webinar Hosted by Xtalks | www.kindevadd.com In this free webinar, learn about microneedle product types and their benefits in drug and vaccine delivery. Attendees will gain insights into analytical characterization methods for ensuring product quality and safety. Th... |
| 09.02.2022 | Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants | FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units... |
| 08.02.2022 | Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants | FREMONT, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units... |
| 08.02.2022 | Zosano Pharma Announces Pricing of $15.4 Million Public Offering of Common Stock and Warrants | FREMONT, CA- February 08, 2022 — Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting ... |
| 19.02.2018 | Life sciences startup Avro aims to deliver drugs to children and the elderly through skin patches | Avro, a life sciences startup in Y Combinator’s current batch, is banking on a method to deliver medications to populations unable to swallow or chew — it will administer them through the skin. Starting with allergy medications, the startup... |
| 07.07.2015 | Morning Read: BioCardia files IPO with hopes of $50M, HHS seeks to protect health of children crossing the border | In response to the influx of Central American children immigrating to the U.S. over the last year, the Department of Health and Human Services (HHS) says it has increased the number of doctors available to treat these unaccompanied minors a... |
| 18.01.2008 | VC funding up, biotech outpaces other industries | Venture-capital funding continued to rise in the fourth quarter, continuing a recent boom despite economic jitters sown by the subprime-mortgage financial mess. VCs tossed $7 billion at startups in the fourth quarter, a substantial 12 perce... |
| 15.11.2007 | Zosano Pharma raises $45M for needle-free drugs | See our story about this Fremont, Calif., specialty pharma in today’s daily briefing at VentureBeat Life Sciences. VentureBeat VentureBeat's mission is to be a digital townsquare for technical decision makers to gain knowledge about transfo... |
| 15.11.2007 | Life sciences briefing: Thursday, Nov. 15, 2007 | Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma EXPANDING ITEMS: Stay tuned. Vaxart receives $3.3M for oral vac... |
| - | Morning Read: BioCardia files IPO with hopes of $50M, HHS seeks to protect health of children crossing the border | TOP STORIES BioCardia, which is expecting to enter its lead cell-based therapy for cardiovascular disease into a Phase 3 trial this year, has now filed paperwork indicating hopes to raise around $50 million in an IPO. – Xconomy The Obama ad... |